Loading
Life sciences · Journal article
British Journal of Clinical Pharmacology · September 17, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Metabolic dysfunction‐associated steatohepatitis (MASH) has emerged as a leading cause of chronic liver disease worldwide and is increasingly recognized as a systemic metabolic‐inflammatory disorder closely linked to cardiovascular risk. Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and emerging incretin‐based multi‐receptor agonists have demonstrated substantial therapeutic potential in this context. Mechanistically, these agents exert integrated effects across the cardiohepatic–metabolic axis. They reduce metabolic burden through appetite suppression and increased energy expenditure, improve hepatic steatosis and inflammation by modulating pathways such as AMP‐activated protein kinase (AMPK), mammalian target of rapamycin (mTOR) and NLRP3 inflammasome signalling and may confer cardiovascular protection through effects on endothelial function and autonomic regulation. Clinically, evidence from large‐scale trials supports distinct benefits across hepatic, heart failure and cardiovascular outcomes. The ESSENCE trial demonstrated MASH resolution and improvements in liver histology, STEP‐HFpEF showed clinically meaningful benefits in patients with obesity‐related HFpEF, and SELECT demonstrated a significant reduction in major adverse cardiovascular events in patients with overweight or obesity and established cardiovascular disease. Importantly, these cardiovascular outcome data should not be interpreted as direct evidence of cardiovascular benefit specifically in patients with biopsy‐confirmed MASH. The relative contributions of weight loss, glycemic improvement and other pharmacological effects remain incompletely defined. Despite these advances, important challenges remain, including uncertainties regarding long‐term outcomes, reliance on surrogate endpoints and incomplete understanding of direct vs. indirect mechanisms of action. Overall, GLP‐1–based and incretin multi‐agonist therapies represent a promising integrative strategy targeting the cardiohepatic–metabolic axis, supporting an emerging therapeutic paradigm for the integrated management of MASH and its associated cardiometabolic complications.